AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
Log in

NASDAQ:TYMETyme Technologies Stock Price, Forecast & News

$1.25
+0.03 (+2.46 %)
(As of 07/10/2020 10:05 AM ET)
Add
Compare
Today's Range
$1.22
Now: $1.25
$1.25
50-Day Range
$1.25
MA: $1.43
$1.64
52-Week Range
$0.86
Now: $1.25
$2.04
Volume63 shs
Average Volume338,433 shs
Market Capitalization$153.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Read More
Tyme Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-22,000,000.00

Miscellaneous

Employees11
Market Cap$153.55 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

How has Tyme Technologies' stock been impacted by COVID-19 (Coronavirus)?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TYME stock has increased by 16.2% and is now trading at $1.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tyme Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tyme Technologies.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tyme Technologies.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies Inc (NASDAQ:TYME) issued its quarterly earnings data on Wednesday, May, 20th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. View Tyme Technologies' earnings history.

What price target have analysts set for TYME?

2 brokerages have issued 12-month target prices for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they anticipate Tyme Technologies' stock price to reach $9.50 in the next year. This suggests a possible upside of 678.7% from the stock's current price. View analysts' price targets for Tyme Technologies.

Has Tyme Technologies been receiving favorable news coverage?

Press coverage about TYME stock has been trending neutral this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tyme Technologies earned a news impact score of 0.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Tyme Technologies.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a decrease in short interest in June. As of June 30th, there was short interest totaling 4,090,000 shares, a decrease of 8.1% from the June 15th total of 4,450,000 shares. Based on an average trading volume of 369,400 shares, the days-to-cover ratio is presently 11.1 days. Approximately 7.5% of the shares of the stock are short sold. View Tyme Technologies' Current Options Chain.

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)
  • Mr. Ben R. Taylor, Pres & CFO (Age 42)
  • Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57)

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.22.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $149.86 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.